Letters to the Editor

Personalized measurable residual disease assays for acute myeloid leukemia guided by whole-genome sequencing

Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD
Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center
Integrated Data Sciences Section, National Institutes of Health, Bethesda, MD
The American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD
Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA
Bio-Rad Laboratories, Digital Biology Group, 5731, W. Las Positias Blvd, Pleasanton, CA
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA
Duke University School of Medicine, Durham, NC
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center
Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center
Haematologica Early view Jul 23, 2026 https://doi.org/10.3324/haematol.2026.300715